Sunday, December 1, 2019

Biocon Biologics to reduce the cost of human insulin and cancer drugs

The Biocon subsidiary will chart a path that ensures high volumes and lowcosts, unlike competitors, Christiane Hamacher, chief executive of Biocon Biologics told ET. https://ift.tt/2RcdZVI https://ift.tt/eA8V8J
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Tens of millions of South Korean retail investors, the market's biggest buyers in 2026, were caught in this week's selloff, as Samsung and SK Hynix tumble (Song Jung-a/Financial Times)

Song Jung-a / Financial Times : Tens of millions of South Korean retail investors, the market's biggest buyers in 2026, were caught i...